Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A 1,2,4-triaminobenzene derivative of formula I:



(I)

wherein:

R^1 is selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, acyl, hydroxy-C_{1-6}-alk(en/yn)yl and hydroxy-C_{3-8}-cycloalk(en)yl;

R^2 and $R^{2'}$ are independently selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, aryl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, aryl-C_{1-6}-alk(en/yn)yl, acyl, hydroxy-C_{1-6}-alk(en/yn)yl and hydroxy-C_{3-8}-cycloalk(en)yl;

R^3 is selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, aryl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, aryl-C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, aryl-C_{3-8}-cycloalk(en)yl, $NR^{10}R^{10'}$-C_{1-6}-alk(en/yn)yl, $NR^{10}R^{10'}$-C_{3-8}-cycloalk(en)yl and hydroxy-C_{3-8}-cycloalk(en)yl[[;]]$_1$ wherein:

R^{10} and $R^{10'}$ are independently selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, hydroxy-C_{3-8}-cycloalk(en)yl, hydroxy-C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, halo-C_{1-6}-alk(en/yn)yl, halo-C_{3-8}-cycloalk(en)yl, halo-C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, cyano-C_{1-6}-alk(en/yn)yl, cyano-C_{3-8}-cycloalk(en)yl and cyano-C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, or

R^{10} and $R^{10'}$ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring [[which]]that optionally contains 1, 2 or 3 further heteroatoms;

X is CO or SO_2;

Z is O or NR^4, wherein:

R^4 is selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl and hydroxy-C_{3-8}-cycloalk(en)yl; or

R^3 and R^4 together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring [[which]]that optionally contains 1, 2 or 3 further heteroatoms, the ring formed by R^3 and R^4 and the nitrogen atom is optionally substituted with one or more substituents independently selected from C_{1-6}-alk(en/yn)yl, aryl and aryl-C_{1-6}-alk(en/yn)yl;

q is 0 or 1; and

Y represents a heteroaryl of formula II:



II

wherein:

W is S;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

p is 0 or 1; and

each R^5 is independently selected from the group consisting of C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, aryl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, aryl-C_{1-6}-alk(en/yn)yl, acyl, halogen, halo-C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, -CO-$NR^6R^{6'}$, cyano, nitro, -$NR^7R^{7'}$, -S-R^8, -SO_2R^8, and SO_2OR^8[[;]], wherein:

R^6 and $R^{6'}$ are independently selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl and aryl;

R^7 and $R^{7'}$ are independently selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, aryl and acyl; and

R^8 is selected from the group consisting of C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, aryl and $-NR^9R^{9'}$[[;]]. [[and]] wherein:

R^9 and $R^{9'}$ are independently selected from the group consisting of hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl and C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl;

or a pharmaceutically acceptable salt [[salts]]thereof.

Claim 2. (previously presented) The compound according to claim 1 wherein R^1 is selected from the group consisting of hydrogen and C_{1-6}-alk(en/yn)yl.

Claim 3. (previously presented) The compound according to claim 1 wherein at least one of the substituents R^2 and $R^{2'}$ is a hydrogen atom.

Claim 4. (previously presented) The compound according to claim 1 wherein both R^2 and $R^{2'}$ are hydrogen atoms.

Claim 5. (previously presented) The compound according to claim 1 wherein **X** is CO.

Claim 6. (previously presented) The compound according to claim 1 wherein **q** is 0.

Claim 7. (previously presented) The compound according to claim 1 wherein **q** is 1 and **Z** is an oxygen atom.

Claim 8. (previously presented) The compound according to claim 1 wherein R^3 is selected from the group consisting of C_{1-6}-alk(en/yn)yl and aryl-C_{1-6}-alk(en/yn)yl.

Claim 9. (previously presented) The compound according to claim 8 wherein R^3 is C_{1-6}-alk(en/yn)yl.

Claim 10. (previously presented) The compound according to claim 8 wherein R^3 is aryl-C_{1-6}-alk(en/yn)yl.

Claim 11. (canceled)

Claim 12. (previously presented) The compound according to claim 1 wherein **W** is a sulfur atom.

Claim 13. (canceled)

Claim 14. (canceled)

Claim 15. (currently amended) The compound according to claim 1 wherein Y is of formula IIb:



IIb

wherein **W, m, n, p** and R^5 are as defined [[above]]in claim 1.

Claim 16. (currently amended) The compound according to claim 1 wherein Y is of formula IIc:



IIc

wherein **W, m, n, p** and R^5 are as defined [[above]]in claim 1.

Claim 17. (previously presented) The compound according to claim 1 wherein each R^5 is independently selected from the group consisting of C_{1-6}-alk(en/yn)yl, aryl, halogen, C_{1-6}-alk(en/yn)yloxy, $-NR^7R^{7'}$, and $-SO_2R^8$.

Claim 18. (currently amended) A compound selected from the group consisting of:
{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-bromo-3-methoxy-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(3-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
(2-Amino-4-{[4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino}-phenyl)-carbamic acid ethyl ester;
{2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-ethyl-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-fluoro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-2-(4-fluoro-phenyl)-acetamide; and
N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-3,3-dimethyl-butyramide;
or a pharmaceutically acceptable salt thereof.

Claim 19. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 in a therapeutically effective amount together with one or more pharmaceutically acceptable carriers or diluents.

Claims 20-25. (canceled)

Claim 26. (currently amended) A method of treating a disorder of the central nervous system in a subject, wherein the disorder of the central nervous system is selected from the group consisting of [[a]] seizure ~~disorder~~, [[a]] neuropathic pain ~~disorder~~, [[a]] migraine pain ~~disorder~~, and [[an]] anxiety~~, disorder, a neurogenerative disorder and a neuronal hyperexcitiation state~~ comprising administering a therapeutically effective amount of the compound of claim 1 to the subject.

Claim 27. (currently amended) The method of claim 26, wherein the seizure ~~disorder~~ is a convulsion, an epilepsy or a status epilepticus.

Claim 28. (currently amended) The method of claim 26, wherein the neuropathic pain ~~disorder~~ is allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy or neuropathic pain related to migraine.

Claim 29. (currently amended) The method of claim 26, wherein the anxiety ~~disorder~~ is anxiety, a generalized anxiety disorder, panic anxiety, an obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, an acute stress reaction, an adjustment disorder, a hypochondriacal disorder, a separation anxiety disorder, agoraphobia, a specific phobia, an anxiety disorder due to a general medical condition or a substance-induced anxiety disorder.

Claims 30-32. (canceled).